• CRISPR Therapeutics granted Chief Technical Officer Sivakesava Sakhamuri 90,000 stock options on November 4, 2026.
• The award also included 40,000 restricted stock units.
• The stock options expire on November 4, 2036.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-452143), on November 06, 2026, and is solely responsible for the information contained therein.